Artwork
iconShare
 
Manage episode 466455517 series 3324141
Content provided by Ohio Chapter of the American College of Cardiology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ohio Chapter of the American College of Cardiology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Please join our special guest, Dr. Benjamin Romer from Ohio State University, as we address the current state of lipid therapy in both primary and secondary prevention patients. He addresses a practical approach to the issue of statin intolerance, then reviews the newer agents including ezetimide and bempedoic acid, as well as the newer percutaneous agents, with a focus on practical tips for implementation. We wrap up with a discussion on the role of coronary calcium scoring to guide therapeutic decisions in select patients.

For more information, see the 2022 ACC Expert Consensus Pathway on the role of Nonstatin Therapies.

Please subscribe to receive updated episodes automatically! Visit https://www.ohioacc.org/cardiohio-podcast/.
“Upbeat Party” by scottholmesmusic.com

  continue reading

Chapters

1. Beyond Statins: A Practical Plan to Incorporate the New Lipid Agents (00:00:00)

2. Statin Intolerance (00:04:27)

3. Direct vs. Calculated LDL (00:08:46)

4. Ezetimide and Bempedoic Acid (00:11:29)

5. PCSK9 and other percutaneous therapies (00:17:17)

6. Calcium Scoring to guide therapy (00:27:50)

25 episodes